Repare Therapeutics Inc
RPTX2.140USD
-0.010-0.47%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
91.99MMarket Cap
LossP/E TTM
More Details of Repare Therapeutics Inc Company
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc Info
Ticker SymbolRPTX
Company nameRepare Therapeutics Inc
IPO dateJun 19, 2020
CEOForte (Steve)
Number of employees129
Security typeOrdinary Share
Fiscal year-endJun 19
Address7210 Frederick-Banting, Suite 100
CityST-LAURENT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeH4S 2A1
Phone18574127018
Websitehttps://www.reparerx.com/
Ticker SymbolRPTX
IPO dateJun 19, 2020
CEOForte (Steve)
Company Executives of Repare Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
31.62K
+6.75%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
+8.59%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
31.62K
+6.75%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
+8.59%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 18
Updated: Thu, Dec 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
23.97%
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
Other
54.51%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
23.97%
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
Other
54.51%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.48%
Investment Advisor/Hedge Fund
10.95%
Investment Advisor
8.96%
Private Equity
7.51%
Individual Investor
0.41%
Venture Capital
0.31%
Research Firm
0.17%
Family Office
0.09%
Other
42.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
151
27.75M
64.60%
-9.51M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
2023Q2
203
37.24M
88.48%
-4.72M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
10.33M
24.05%
--
--
Jun 30, 2025
Blue Owl Capital Holdings LP
3.44M
8.02%
+71.16K
+2.11%
Jun 30, 2025
OrbiMed Advisors, LLC
3.32M
7.73%
+122.13K
+3.82%
Jun 30, 2025
Redmile Group, LLC
1.59M
3.69%
-298.21K
-15.83%
Jun 30, 2025
MPM Capital Inc.
1.12M
2.61%
--
--
Jun 30, 2025
MPM BioImpact LLC
819.92K
1.91%
--
--
Jun 30, 2025
Renaissance Technologies LLC
522.86K
1.22%
+224.20K
+75.07%
Jun 30, 2025
Citadel Advisors LLC
937.49K
2.18%
--
--
Jun 30, 2025
Rangeley Capital LLC
355.29K
0.83%
+355.29K
--
Jun 30, 2025
Acadian Asset Management LLC
681.18K
1.59%
+40.85K
+6.38%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
SPDR S&P International Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Repare Therapeutics Inc?
The top five shareholders of Repare Therapeutics Inc are:
BVF Partners L.P. holds 10.33M shares, accounting for 24.05% of the total shares.
Blue Owl Capital Holdings LP holds 3.44M shares, accounting for 8.02% of the total shares.
OrbiMed Advisors, LLC holds 3.32M shares, accounting for 7.73% of the total shares.
Redmile Group, LLC holds 1.59M shares, accounting for 3.69% of the total shares.
MPM Capital Inc. holds 1.12M shares, accounting for 2.61% of the total shares.
BVF Partners L.P. holds 10.33M shares, accounting for 24.05% of the total shares.
Blue Owl Capital Holdings LP holds 3.44M shares, accounting for 8.02% of the total shares.
OrbiMed Advisors, LLC holds 3.32M shares, accounting for 7.73% of the total shares.
Redmile Group, LLC holds 1.59M shares, accounting for 3.69% of the total shares.
MPM Capital Inc. holds 1.12M shares, accounting for 2.61% of the total shares.
What are the top three shareholder types of Repare Therapeutics Inc?
The top three shareholder types of Repare Therapeutics Inc are:
BVF Partners L.P.
Blue Owl Capital Holdings LP
OrbiMed Advisors, LLC
BVF Partners L.P.
Blue Owl Capital Holdings LP
OrbiMed Advisors, LLC
How many institutions hold shares of Repare Therapeutics Inc (RPTX)?
As of 2025Q3, 151 institutions hold shares of Repare Therapeutics Inc, with a combined market value of approximately 27.75M, accounting for 64.60% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.57%.
What is the biggest source of revenue for Repare Therapeutics Inc?
In --, the -- business generated the highest revenue for Repare Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
